About J. Michael Gonzalez-Campoy, MD, PhD, FACE
J. Michael Gonzalez-Campoy, MD, PhD, FACE, is medical director and CEO of the Minnesota Center for Obesity, Metabolism, and Endocrinology (MNCOME). He is a recognized national expert on diabetes and obesity and a proponent of adiposopathy as a treatment target.
Dr. Gonzalez-Campoy is clinical assistant professor of medicine at the University of Minnesota. He is board certified in endocrinology, diabetes, and metabolism. He has been a member of the Board of Directors of the American Association of Clinical Endocrinologists (AACE) since 2005 and is a member of the Board of Directors of the American College of Endocrinology (ACE).
Dr. Gonzalez-Campoy received his MD and PhD (PhD in physiology and biophysics) from Mayo Medical School and Mayo Graduate School in Rochester, MN. He completed his residency in internal medicine at the Mayo Graduate School of Medicine. Dr. Gonzalez-Campoy concluded his training with a fellowship in diabetes, endocrinology, and metabolism at the University of Minnesota in Minneapolis, MN.
Dr. Gonzalez-Campoy is the first Hispanic past president of the Minnesota Medical Association and held the designated position for a minority physician at the House of Delegates of the American Medical Association at its inception. In addition, he represents AACE as a member of the Steering Committee for the National Diabetes Education Program.
Dr. Gonzalez-Campoy is dedicated to advancing the care of patients with obesity. He has authored the Power of Prevention website content on obesity, co-authored the AACE clinical practice guidelines on bariatric surgery and obesity, and is working diligently to validate the concept that the adipocyte is an endocrine cell and a treatment target for endocrinologists.
National Diabetes Education Program (NDEP). Guiding Principles for Diabetes Care: For Health Care Professionals. NIH Publication No. 09-4343 NDEP-16. Revised April 2009.
Bays HE, Gonzalez-Campoy JM, Henry RR, Bergman DA. Kitabchi AE, Schorr AB. Rodbard HW. The Adiposopathy Working Group. Is adiposopathy (sick fat) an endocrine disease? Int J Clin Pract. 2008;62(10):1474-83. Epub 2008 Aug 4.
Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML, Guven S, Spitz AF, Apovian CM, Livingston EH, Brolin R, Sarwer DB, Anderson WA, and Dixon J. Executive Summary Of The Recommendations Of The American Association Of Clinical Endocrinologists, The Obesity Society, And American Society For Metabolic & Bariatric Surgery Medical Guidelines For Clinical Practice For The Perioperative Nutritional, Metabolic, And Nonsurgical Support Of The Bariatric Surgery Patient. Endocr Pract. 2008;14(3):318-36.
Bays HE, Gonzalez-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, and Henry RR. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008;6(3): 343-368.
Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, and Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vascular Medicine. 2007;12:311–318.
Bank AJ, Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM. The effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens. 2007;20(7):777-83.
Minnesota Medical Association Obesity Task Force. How to Evaluate and Treat Obesity. Minnesota Medicine. 2005;88:40-46.
The Report of the Minnesota Medical Association Health Care Reform Task Force. Minnesota Medicine. 2005;88:Supplement.
Gonzalez-Campoy RC, Gonzalez-Campoy JM. Minnesota Diabetes Plan 2010. Minnesota Medicine. 2003;86:44-48.
Minnesota Diabetes Plan 2010. Recommendations from Minnesota’s Diabetes Community. Facilitated by the Minnesota Department of Health. September, 2003. www.health.state.mn.us/diabetes/2010plan
Hensrud D, Billington C, Blum HT, Gonzalez-Campoy JM, Ramsey S. ICSI Technology Assessment: Pharmacological Approaches to Weight Loss in Adults. 2003. http://www.icsi.org/knowledge/detail.asp?catID=107&itemID=785
Gonzalez-Campoy JM, Long C, Roberts D, Berndt T, Romero JC, Knox FG. Renal interstitial hydrostatic pressure and PGE2 in pressure natriuresis. Am J Physiol (Fluid Electrolyte Metabolism). 1991;260(5):F643-F649.
Gonzalez-Campoy JM, Awazu M, Granger JP, Haas JA, Romero JC, Knox FG. Blunted Pressure Natriuresis in the Brattleboro Diabetes Insipidus Rat. Hypertension. 1989;13:322-326.
Gonzalez-Campoy JM, Kachelski J, Burnett, Jr. JC, Granger JP, Romero JC, Knox FG. Proximal Tubule Response in Aldosterone Escape. Am J Physiol (Regulatory Integrative Comp. Physiol). 1989;256(1):R86-R90.
Chiou RK, Vessella RL, Elson MK, Clayman RV, Gonzalez-Campoy JM, Klicka MJ, Shafer RB, Lange PH. Localization of human renal cell carcinoma xenografts with a tumor-preferential monoclonal antibody. Cancer Research. 1985;45:6140-6146.
Gonzalez-Campoy JM. Temporal and regional characteristics of cerebral vascular responses to sympathetic nerve stimulation. Abbreviated Reports by Research Participants in the Secondary Student Training Program. 1978;2:73-75, University of Iowa, Iowa City, Iowa.
Financial Disclosures for J. Michael Gonzalez-Campoy, MD, PhD, FACE
DiabeticLifestyle, a Vertical Health, LLC website, is committed to ensuring that the medical information it presents is accurate, balanced, objective, and trustworthy.
To help achieve this goal, DiabeticLifestyle requires all authors, editors, and reviewers to disclose any financial relationships or affiliations they have with companies whose products or services may be mentioned in the content they author, edit, or review.
The intent of this policy is to identify any perceived, potential, or real conflicts of interest so that readers can make their own judgments about the value of information being presented.